Quality of Life and Burden of Moderate-to-Severe Atopic Dermatitis in Adult Patients Within the Asia–Pacific Region: A Cross-sectional Survey
This multinational survey study showed that AD is associated with substantial QoL impairment and economic burden among Asian adult patients with moderate-to-severe AD. To alleviate burden of AD, clinicians should be more proactive in managing other concomitant conditions including psychological issues, and advocate for increased reimbursement for AD treatments.
Authors
- Siriwan Wananukul (ORCID: https://orcid.org/0000-0002-7664-6049)
- Yoko Kataoka (ORCID: https://orcid.org/0000-0001-6268-6587)
- Yung Chan (ORCID: https://orcid.org/0000-0002-3330-329X)
- Sang Wook Son (ORCID: https://orcid.org/0000-0002-3332-7056)
- N. D. R. Bhat (ORCID: https://orcid.org/0000-0002-8383-5059)
- Sean Gardiner (ORCID: https://orcid.org/0009-0008-9193-9844)
- See‐Hwee Yeo (ORCID: https://orcid.org/0000-0001-8658-8172)
- Chia‐Yu Chu (ORCID: https://orcid.org/0000-0002-9370-3279)
- Nisha Suyien Chandran (ORCID: https://orcid.org/0000-0001-8225-0035)
- Bozhi Chen (ORCID: https://orcid.org/0000-0003-2874-1786)
- Hao Cheng (ORCID: https://orcid.org/0000-0001-5089-6747)
- Qi Qing Ng
- Han-Fang Liao
Institutions
- Chulalongkorn University (TH)
- Father Muller Medical College Hospital (IN)
- Pfizer (United States) (US)
- Korea University (KR)
- King Chulalongkorn Memorial Hospital (TH)
- Sir Run Run Shaw Hospital (CN)
- Osaka Prefectural Medical Center (JP)
- National Taiwan University Hospital (TW)
- National University Hospital (SG)
- Zhejiang University (CN)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1007/s13555-024-01244-7
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.14
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Regeneron Pharmaceuticals
- Mylan
- Lion Corporation
- Pfizer Hong Kong
- Galderma